# A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

> **NCT07088926** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 435 (estimated)

## Conditions studied

- Bronchiectasis With Pseudomonas Aeruginosa Colonization

## Interventions

- **BIOLOGICAL:** AZD0292
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07088926
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2027-12-09
- **Final completion:** 2028-06-14
- **Target enrollment:** 435 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07088926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07088926, "A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07088926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*